Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Li, Guobing ^a   Shan, Changyu ^a   Liu, Lei ^a   Zhou, Ting ^a   Zhou, Jing ^a   Hu, Xiaoye ^a   Chen, Yibiao ^b   Cui, Hongjuan ^b   Gao, Ning ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b SOUTHWEST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; S6 KINASE; TANSHINONE IIA; TUBULIN; VASCULOTROPIN; ABIETANE DERIVATIVE; ANTINEOPLASTIC AGENT; EIF4EBP1 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PHOSPHOPROTEIN; PROTEIN S6; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TANSHINONE; TARGET OF RAPAMYCIN KINASE; TUMOR PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST TUMOR; CANCER INHIBITION; CAPILLARY DENSITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN STABILITY; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; TRANSLATION REGULATION; ANIMAL; BIOSYNTHESIS; BREAST NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

EUKARYOTA; MAMMALIA; MUS MUSCULUS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DITERPENES, ABIETANE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHOPROTEINS; RIBOSOMAL PROTEIN S6; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922496579     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117440     Document Type: Article

References (42)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300. doi: 10.3322/caac.20073 PMID: 20610543
2. Miller KD, Dul CL (2004) Breast cancer: the role of angiogenesis and antiangiogenic therapy. Hematol Oncol Clin North Am 18: 1071-1086. PMID: 15474336
3. Boudreau N, Myers C (2003) Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res 5: 140-146. PMID: 12793895
4. Vaupel P, Mayer A, Briest S, Hockel M (2005) Hypoxia in breast cancer: role of blood flow, oxygen diffusion distances, and anemia in the development of oxygen depletion. Adv Exp Med Biol 566: 333-342. PMID: 16594170
5. Chakraborty G, Rangaswami H, Jain S, Kundu GC (2006) Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis. J Biol Chem 281: 11322-11331. PMID: 16474166
6. Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P, et al. (2005) Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 46: 31-36. PMID: 15656883
7. McMahon G (2000) VEGF receptor signaling in tumor angiogenesis. Oncologist 5 Suppl 1: 3-10.
8. Chen CT, Du Y, Yamaguchi H, Hsu JM, Kuo HP, et al. (2012) Targeting the IKKbeta/mTOR/VEGF signaling pathway as a potential therapeutic strategy for obesity-related breast cancer. Mol Cancer Ther 11: 2212-2221. doi: 10.1158/1535-7163.MCT-12-0180 PMID: 22826466
9. Chekhonin VP, Shein SA, Korchagina AA, Gurina OI (2013) VEGF in tumor progression and targeted therapy. Curr Cancer Drug Targets 13: 423-443. PMID: 23167597
10. Goldberg MA, Schneider TJ (1994) Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 269: 4355-4359. PMID: 8308005
11. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, et al. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613. PMID: 8756616
12. Harris AL (2002) Hypoxia-a key regulatory factor in tumor growth. Nat Rev Cancer 2: 38-47. PMID: 11902584
13. Zhong Q, Zhou Y, Ye W, Cai T, Zhang X, et al. (2012) Hypoxia-inducible factor 1-alpha-AA-modified bone marrow stem cells protect PC12 cells from hypoxia-induced apoptosis, partially through VEGF/PI3K/Akt/FoxO1 pathway. Stem Cells Dev 21: 2703-2717. doi: 10.1089/scd.2011.0604 PMID: 22468883
14. Ivan M, Kondo K, Yang H, Kim W, Valiando J, et al. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464-468. PMID: 11292862
15. Maxwell PH, Ratcliffe PJ (2002) Oxygen sensors and angiogenesis. Semin Cell Dev Biol 13: 29-37. PMID: 11969369
16. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, et al. (2002) Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8: 1831-1837. PMID: 12060624
17. Shibaji T, Nagao M, Ikeda N, Kanehiro H, Hisanaga M, et al. (2003) Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res 23: 4721-4727. PMID: 14981919
18. Sumiyoshi Y, Kakeji Y, Egashira A, Mizokami K, Orita H, et al. (2006) Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res 12: 5112-5117. PMID: 16951228
19. Van den Eynden GG, Smid M, Van Laere SJ, Colpaert CG, Van der Auwera I, et al. (2008) Gene expression profiles associated with the presence of a fibrotic focus and the growth pattern in lymph nodenegative breast cancer. Clin Cancer Res 14: 2944-2952. doi: 10.1158/1078-0432.CCR-07-4397 PMID: 18483361
20. Wang X, Morris-Natschke SL, Lee KH (2007) New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med Res Rev 27: 133-148. PMID: 16888751
21. Li X, Xu X, Wang J, Yu H, Wang X, et al. (2012) A system-level investigation into the mechanisms of Chinese Traditional Medicine: Compound Danshen Formula for cardiovascular disease treatment. PLoS One 7: e43918. doi: 10.1371/journal.pone.0043918 PMID: 22962593
22. Gao S, Liu Z, Li H, Little PJ, Liu P, et al. (2012) Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis 220: 3-10. doi: 10.1016/j.atherosclerosis.2011.06.041 PMID: 21774934
23. Wang X, Wei Y, Yuan S, Liu G, Lu Y, et al. (2005) Potential anticancer activity of tanshinone IIA against human breast cancer. Int J Cancer 116: 799-807. PMID: 15849732
24. Su CC, Lin YH (2008) Tanshinone IIA inhibits human breast cancer cells through increased Bax to BclxL ratios. Int J Mol Med 22: 357-361. PMID: 18698495
25. Gong Y, Li Y, Abdolmaleky HM, Li L, Zhou JR (2012) Tanshinones inhibit the growth of breast cancer cells through epigenetic modification of Aurora A expression and function. PLoS One 7: e33656. doi: 10.1371/journal.pone.0033656 PMID: 22485147
26. Tsai MY, Yang RC, Wu HT, Pang JH, Huang ST (2011) Anti-angiogenic effect of Tanshinone IIA involves inhibition of matrix invasion and modification of MMP-2/TIMP-2 secretion in vascular endothelial cells. Cancer Lett 310: 198-206. doi: 10.1016/j.canlet.2011.06.031 PMID: 21788102
27. Li G, Zhou T, Liu L, Chen J, Zhao Z, et al. (2013) Ezrin dephosphorylation/downregulation contributes to ursolic acid-mediated cell death in human leukemia cells. Blood Cancer J 3: e108. doi: 10.1038/bcj. 2013.7 PMID: 23584398
28. Garcia-Maceira P, Mateo J (2009) Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 28: 313-324. doi: 10.1038/onc.2008.398 PMID: 18978810
29. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6. PMID: 1688381
30. Kakeya H, Osada H (2004) [Development of novel angiogenesis inhibitors targeting VEGF (vascular endothelial growth factor) for cancer chemotherapy]. Nihon Rinsho 62: 1264-1270. PMID: 15283142
31. Longo F, Mansueto G (2006) [Novel methods of treatment for colorectal carcinoma: from oral chemotherapy to angiogenesis inhibitors]. Tumori 92: suppl 1-15.
32. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, et al. (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3: 363-375. PMID: 12726862
33. Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loophelix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92: 5510-5514. PMID: 7539918
34. Rankin EB, Wu C, Khatri R, Wilson TL, Andersen R, et al. (2012) The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell 149: 63-74. doi: 10.1016/j.cell.2012.01.051 PMID: 22464323
35. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25. PMID: 9034784
36. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, et al. (2006) Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12: 122-127. PMID: 16341243
37. Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103: 253-262. PMID: 11057898
38. Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335-348. PMID: 15122205
39. van den Beucken T, Koritzinsky M, Wouters BG (2006) Translational control of gene expression during hypoxia. Cancer Biol Ther 5: 749-755. PMID: 16861930
40. Duong MT, Akli S, Wei C, Wingate HF, Liu W, et al. (2012) LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet 8: e1002538. doi: 10.1371/journal.pgen.1002538 PMID: 22479189
41. Schwarzlose-Schwarck S, Scholz CW, Regierer AC, Martus P, Neumann C, et al. (2012) The mTOR inhibitor everolimus in combination with carboplatin in metastatic breast cancer-a phase I trial. Anticancer Res 32: 3435-3441. PMID: 22843927
42. Montero JC, Esparis-Ogando A, Re-Louhau MF, Seoane S, Abad M, et al. (2012) Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene 33: 148-156. doi: 10.1038/onc.2012.572 PMID: 23246963